Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Average: 2023-2025

Historic Equity Average for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to $11.3 million.

  • InMed Pharmaceuticals' Equity Average rose 42.18% to $12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 42.18%. This contributed to the annual value of $11.3 million for FY2025, which is 6.31% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Equity Average stood at $11.3 million for FY2025, which was up 6.31% from $10.6 million recorded in FY2024.
  • InMed Pharmaceuticals' Equity Average's 5-year high stood at $11.3 million during FY2025, with a 5-year trough of $10.6 million in FY2023.
  • Over the past 3 years, InMed Pharmaceuticals' median Equity Average value was $10.6 million (recorded in 2024), while the average stood at $10.9 million.
  • In the last 5 years, InMed Pharmaceuticals' Equity Average decreased by 0.60% in 2024 and then increased by 6.31% in 2025.
  • MRY analysis of 3 years shows InMed Pharmaceuticals' Equity Average stood at $10.6 million in 2023, then grew by 0.60% to $10.6 million in 2024, then increased by 6.31% to $11.3 million in 2025.
  • Its last three reported values are $11.3 million in FY2025, $10.6 million for FY2024, and $10.6 million during FY2023.